A team with deep cell therapy development expertise across chemistry, manufacturing, business development, IP, legal, finance, and clinical development.
Christopher brings extensive experience in biotech company formation, intellectual property strategy, and business development. He has guided early-stage life sciences companies from inception through clinical development, with a focus on building the legal and operational foundations that enable scientific teams to move quickly.
Nicholas is a scientist and entrepreneur with expertise in cell therapy and immunology. He has led research programs at the intersection of synthetic biology and cancer immunotherapy, and brings hands-on experience translating academic discoveries into therapeutic candidates.
Dr. Deiters is a Professor of Chemistry at the University of Pittsburgh. His laboratory pioneered the use of optogenetic and chemical biology tools to control gene expression and protein function, providing key enabling technology underlying Monarch's adaptor platform.
Dr. Lohmueller is an Assistant Professor of Immunology at the University of Pittsburgh. His research focuses on engineering synthetic immune receptors and CAR T cell therapies for solid tumors, with particular emphasis on overcoming the immunosuppressive tumor microenvironment.
Monarch is supported by a network of leading scientists and clinicians in oncology, immunology, and cell therapy.
We're always looking for exceptional scientists and operators.